Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

FRSX vs EVGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVGN Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–2 Matrix Metrics)

EVGN Overall Winner 6-Pillar Tally: FRSX 2 – 2 EVGN (2 Tie) Matrix Metrics: FRSX 2 – 4 EVGN

As of Nov 17, 2026, Evogene Ltd. (EVGN) is the stronger overall head-to-head candidate over Foresight Autonomous Holdings Ltd. (FRSX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). FRSX carries a Unified Composite Score of 40.4/100 (SELL) at $0.47 (N/M Forward P/E, -2642.2% operating margin), whereas EVGN carries 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin).

  • Growth vs. Quality Trade-Off: EVGN earns the overall head-to-head edge with a stronger Unified Composite Score (44.1/100 HOLD vs. FRSX 40.4/100 SELL) and 1.37β · 138% Vol risk profile, whereas FRSX leads top-line expansion (-32.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FRSX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile EVGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FRSX vs EVGN
FRSX NASDAQ
Foresight Autonomous Holdings Ltd. American Depositary Shares
Services-Prepackaged Software
$0.47
-5.82% 1D
Market Cap $2.0M
TTM Revenue $445,000
Forward P/E N/M
Beta / 30D Vol 1.23β · 57% Vol
Unified Composite Score
40.4 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.7%), weak momentum, RSI 17
RSI-14: 17.4 · SMA20: $0.65 · SMA50: $0.88
EVGN NASDAQ Head-to-Head Winner
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.37β · 138% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 42.0 Fund 44.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 44
RSI-14: 44.5 · SMA20: $0.36 · SMA50: $0.40

6-Pillar Scorecard Institutional Category Breakdown (FRSX 2 – 2 EVGN)

Columns: Metric · FRSX · EVGN
1. Valuation Multiples FRSX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 4.5x N/M
2. Growth & Scale FRSX
Revenue Growth (YoY) -32.8% -60.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $445,000 $1.7M
Market Cap $2.0M $6.0M
3. Profitability & Quality EVGN
Gross Margin 65.4% -67.6%
Operating Margin -2642.2% -858.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -205.9% -182.8%
4. Balance Sheet & Cash Flow EVGN
Cash Generation (TTM) -$12M EBITDA -$11M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.71 Book/Sh · -205.9% ROE $6.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Auto Parts Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FRSX (2) vs EVGN (4)
Institutional Metric FRSX EVGN Criterion Row Edge
Market Capitalization
Scale
$2.0M $6.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-32.8% -60.7% Higher Growth FRSX
Operating Margin (TTM)
Profitability
-2642.2% -858.2% Higher Margin EVGN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-205.9% -182.8% Higher ROE EVGN
52-Week Range Position
Momentum
0% ($0–$3) 9% ($0–$1) Stronger Trend EVGN
Beta / 30D Volatility
Risk Regime
1.23β · 57% Vol 1.37β · 138% Vol Lower Realized Risk FRSX
Unified Institutional Score
Composite Signal
40.4 / 100 (SELL) 44.1 / 100 (HOLD) Higher Composite EVGN
Trailing 12M Revenue (USD)
Operating Scale
$445,000 $1.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.4% -67.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($1.71 Book/Sh · -205.9% ROE) -$11M ($6.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVGN +34.15 pp
FRSX: -41.73% · EVGN: -7.58%
3M Horizon EVGN +16.34 pp
FRSX: -59.74% · EVGN: -43.4%
6M Horizon EVGN +22.16 pp
FRSX: -76.45% · EVGN: -54.29%
1Y Horizon EVGN +6.3 pp
FRSX: -78.19% · EVGN: -71.89%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FRSX vs EVGN. Trailing 12-month operating profitability (FRSX -2642.2% vs EVGN -858.2%) and valuation multiples (FRSX N/M vs EVGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FRSX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$445,000
Gross Margin65.4%
Op. Margin-2642.2%
ROE / Fwd P/E-205.9% · N/M
EVGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.7M
Gross Margin-67.6%
Op. Margin-858.2%
ROE / Fwd P/E-182.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FRSX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FRSX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FRSX Moat Profile Cyclical / Execution-Driven Positioning
Auto Parts Operator
Competes within the Auto Parts value chain with $2.0M market capitalization and -2642.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FRSX vs EVGN Key Questions & Quantitative Answers

As of Nov 17, 2026, Evogene Ltd. (EVGN) is the stronger overall head-to-head candidate over Foresight Autonomous Holdings Ltd. (FRSX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). FRSX carries a Unified Composite Score of 40.4/100 (SELL) at $0.47 (N/M Forward P/E, -2642.2% operating margin), whereas EVGN carries 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin). Growth vs. Quality Trade-Off: EVGN earns the overall head-to-head edge with a stronger Unified Composite Score (44.1/100 HOLD vs. FRSX 40.4/100 SELL) and 1.37β · 138% Vol risk profile, whereas FRSX leads top-line expansion (-32.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FRSX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile EVGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FRSX leads the Growth & Scale pillar: FRSX posts -32.8% YoY revenue growth and +0.0% YoY earnings growth on $445,000 TTM revenue (65.4% gross margin, -2642.2% operating margin), compared with EVGN at -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin). On trailing 12-month operating scale, FRSX generates $445,000 in USD-normalized revenue versus $1.7M for EVGN. In operating R&D and SG&A reinvestment, FRSX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVGN.

FRSX screens cheaper on headline valuation multiples. FRSX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.5x EV/Revenue (unreported EBITDA margin), whereas EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FRSX (-205.9% ROE) versus EVGN (-182.8% ROE) capital efficiency.

In options market volatility and institutional positioning, FRSX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 57% Vol realized risk). By comparison, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.